stockrowVera Therapeutics, Inc.
VERA Healthcare Biotechnology
- EPS
- −26.7%
- Free cash flow
- −82.5%
- Total debt
- +1.03%
Quarter to June 2026, against a year earlier
Follow VERA
Alert me
Vera Therapeutics, Inc. (VERA) Return on equity
Vera Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was −91.8%, down 41.0 percentage points from fiscal 2025 (−50.7%). Over the past ten years it has ranged from −121.6% (fiscal 2022) to 330.1% (fiscal 2021); the current reading is higher than 43% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −50.7% | (5.88) |
| FY2024 | −44.8% | 62.67 |
| FY2023 | −107.5% | 14.08 |
| FY2022 | −121.6% | (451.70) |
| FY2021 | 330.1% | 245.27 |
| FY2020 | 84.9% | 66.02 |
| FY2019 | 18.8% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| ADMA ADMA Biologics Inc compare | 42.0% |
| VCEL Vericel Corporation compare | 9.44% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| IMNM Immunome, Inc. compare | −64.0% |
| VERA Vera Therapeutics, Inc. | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)